
    
      Phase 1a is a dose escalation study in patients with histologically/cytologically confirmed
      ovarian cancer that are platinum-resistant or refractory. Phase 1b is an expansion study
      where patients will be enrolled and treated at recommended dose and schedule based on the
      Phase 1a.
    
  